CHEK2 and prostate carcinoma: In this study, we expand on these results by conducting further in silico analyses on the variants prioritized in a family and identifying three potentially disease-causing germline variants in CHEK2, EWSR1, and TIAM1. The CHEK2 variant we identified (p.E239K) has already been reported as a germline variant in breast and prostate cancers (11, 12).